April 2, 2025

Compounding Pharmacy: Trends and Best Practices for Private Equity

At the forefront of innovation, compounding pharmacies are reshaping healthcare by providing tailored, patient-centric solutions. With a $6B market poised for 6.1% annual growth, the sector addresses critical gaps in medication shortages, rising drug costs, and the demand for personalized medicine.

What you'll learn:

The Market potential with room for consolidation and scaling
Growth drivers for the industry
Private equity opportunities for investing

Whether you're an investor, a healthcare provider, or a patient, compounding pharmacies offer a unique opportunity to create impactful change in the pharmaceutical landscape.

Download the Report

Press Releases

ALVAREZ & MARSAL BOLSTERS ITS HEALTHCARE PRACTICE IN SOUTHEAST ASIA (ASEAN) REGION WITH THE APPOINTMENT OF SANATH KUMAR AS MANAGING DIRECTOR

September 1, 2025

Leading global professional services firm Alvarez & Marsal (A&M) has announced the appointment of Sanath Kumar as Managing Director within its Southeast Asia and Australia (SEAA) business unit. Based in Singapore, Mr. Sanath will play a strategic role in building out A&M’s Healthcare and Life Sciences practice across ASEAN markets.

Thought Leadership

Next-Generation Antibodies: A New Era in Immuno-Oncology

August 25, 2025

As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.

Thought Leadership

Strategic Patience in GenAI - A smarter path to AI leadership

August 11, 2025

As Generative AI accelerates across industries, life sciences firms must seek to adopt strategic patience, prioritizing long-term enterprise value over generating short-term media headlines.

Thought Leadership

The U.S. Pharma Premium: Who’s Really Paying the Price?

June 30, 2025

For decades, the United States has shouldered a disproportionate share of global pharmaceutical costs, accounting for 70% of global biopharma profits and over 80% of new drug launches. While this has helped drive significant medical innovation and supported the majority of global drug launches, it has also resulted in higher out-of-pocket costs for American patients.

Authors